VEGFA and neoplasm: Notably, pharmacological inhibition of tumour-cell-specific cyclooxygenase (COX)-2 leads to reduced expression of VEGF and, consequently, of PFKFB3, the gene that encodes 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, in the TECs.